Compile Data Set for Download or QSAR
Report error Found 214 Enz. Inhib. hit(s) with all data for entry = 8541
TargetOrexin/Hypocretin receptor type 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM256956(US9493432, 82)
Affinity DataT: 2°CAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2017
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM256909(US9493432, 33)
Affinity DataT: 2°CAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2017
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM256918(US9493432, 42)
Affinity DataT: 2°CAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2017
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM256921(US9493432, 45)
Affinity DataT: 2°CAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2017
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM256928(US9493432, 52)
Affinity DataT: 2°CAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2017
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM256931(US9493432, 55)
Affinity DataT: 2°CAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2017
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM256932(US9493432, 56)
Affinity DataT: 2°CAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2017
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM256933(US9493432, 57)
Affinity DataT: 2°CAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2017
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM256934(US9493432, 58)
Affinity DataT: 2°CAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2017
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM256956(US9493432, 82)
Affinity DataT: 2°CAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2017
Entry Details
Go to US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM256877(US9493432, 1)
Affinity DataIC50: 0.840nMT: 2°CAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2017
Entry Details
Go to US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM256953(US9493432, 79)
Affinity DataIC50: 1nMT: 2°CAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2017
Entry Details
Go to US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM256954(US9493432, 80)
Affinity DataIC50: 1nMT: 2°CAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2017
Entry Details
Go to US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM256955(US9493432, 81)
Affinity DataIC50: 1nMT: 2°CAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2017
Entry Details
Go to US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM256957(US9493432, 83)
Affinity DataIC50: 1nMT: 2°CAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2017
Entry Details
Go to US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM256879(US9493432, 3)
Affinity DataIC50: 4.20nMT: 2°CAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2017
Entry Details
Go to US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM256910(US9493432, 34)
Affinity DataIC50: 4.70nMT: 2°CAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2017
Entry Details
Go to US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM256949(US9493432, 75)
Affinity DataIC50: 5nMT: 2°CAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2017
Entry Details
Go to US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM256911(US9493432, 35)
Affinity DataIC50: 6.70nMT: 2°CAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2017
Entry Details
Go to US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM256979(US9493432, 107)
Affinity DataIC50: 7nMT: 2°CAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2017
Entry Details
Go to US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM256912(US9493432, 36)
Affinity DataIC50: 8.30nMT: 2°CAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2017
Entry Details
Go to US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM256913(US9493432, 37)
Affinity DataIC50: 11nMT: 2°CAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2017
Entry Details
Go to US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM256935(US9493432, 59)
Affinity DataIC50: 11nMT: 2°CAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2017
Entry Details
Go to US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM256880(US9493432, 4)
Affinity DataIC50: 12nMT: 2°CAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2017
Entry Details
Go to US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM256881(US9493432, 5)
Affinity DataIC50: 12nMT: 2°CAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2017
Entry Details
Go to US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM256973(US9493432, 99)
Affinity DataIC50: 12nMT: 2°CAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2017
Entry Details
Go to US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM256892(US9493432, 16)
Affinity DataIC50: 13nMT: 2°CAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2017
Entry Details
Go to US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM256914(US9493432, 38)
Affinity DataIC50: 13nMT: 2°CAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2017
Entry Details
Go to US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM256982(US9493432, 104)
Affinity DataIC50: 13nMT: 2°CAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2017
Entry Details
Go to US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM256980(US9493432, 108)
Affinity DataIC50: 13nMT: 2°CAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2017
Entry Details
Go to US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM256915(US9493432, 39)
Affinity DataIC50: 14nMT: 2°CAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2017
Entry Details
Go to US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM256946(US9493432, 72)
Affinity DataIC50: 14nMT: 2°CAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2017
Entry Details
Go to US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM256966(US9493432, 92)
Affinity DataIC50: 14nMT: 2°CAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2017
Entry Details
Go to US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM256967(US9493432, 93)
Affinity DataIC50: 14nMT: 2°CAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2017
Entry Details
Go to US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM256895(US9493432, 19)
Affinity DataIC50: 15nMT: 2°CAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2017
Entry Details
Go to US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM256916(US9493432, 40)
Affinity DataIC50: 15nMT: 2°CAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2017
Entry Details
Go to US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM256943(US9493432, 69)
Affinity DataIC50: 15nMT: 2°CAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2017
Entry Details
Go to US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM256917(US9493432, 41)
Affinity DataIC50: 16nMT: 2°CAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2017
Entry Details
Go to US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM256964(US9493432, 90)
Affinity DataIC50: 16nMT: 2°CAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2017
Entry Details
Go to US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM256978(US9493432, 105)
Affinity DataIC50: 17nMT: 2°CAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2017
Entry Details
Go to US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM256897(US9493432, 21)
Affinity DataIC50: 18nMT: 2°CAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2017
Entry Details
Go to US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM256965(US9493432, 91)
Affinity DataIC50: 18nMT: 2°CAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2017
Entry Details
Go to US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM256952(US9493432, 78)
Affinity DataIC50: 20nMT: 2°CAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2017
Entry Details
Go to US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM256961(US9493432, 87)
Affinity DataIC50: 21nMT: 2°CAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2017
Entry Details
Go to US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM256962(US9493432, 88)
Affinity DataIC50: 21nMT: 2°CAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2017
Entry Details
Go to US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM256974(BDBM256975 | US9493432, 100)
Affinity DataIC50: 22nMT: 2°CAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2017
Entry Details
Go to US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM256898(US9493432, 22)
Affinity DataIC50: 23nMT: 2°CAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2017
Entry Details
Go to US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM256950(US9493432, 76)
Affinity DataIC50: 23nMT: 2°CAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2017
Entry Details
Go to US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM256959(US9493432, 85)
Affinity DataIC50: 23nMT: 2°CAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2017
Entry Details
Go to US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM256918(US9493432, 42)
Affinity DataIC50: 24nMT: 2°CAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2017
Entry Details
Go to US Patent

Displayed 1 to 50 (of 214 total ) | Next | Last >>
Jump to: